Search This Blog

Wednesday, November 6, 2019

Ionis up on profitable Q3, guidance boost

Ionis Pharmaceuticals (NASDAQ:IONS) Q3 results:
Revenues: $168M (+15.9%); Spinraza royalties: $82M (+17.1%).
Global Spinraza sales up 25% ytd to over $1.5B.
Net income: $26M (+620.0%); non-GAAP net income: $39M (+44.4%); EPS: $0.18 (+700.0%).
Initiate Phase 3 program for AKCEA-TTR-Lrx this quarter.
2019 guidance: Revenue: ~$1B from >$725M; net income: >$300M from net income positive.
Shares up 4% premarket on light volume.
Previously: Ionis Pharmaceuticals EPS beats by $0.60, beats on revenue (Nov. 6)
Posted by at No comments:

Acceleron Pharma EPS misses by $0.04, misses on revenue

Acceleron Pharma (NASDAQ:XLRN): Q3 GAAP EPS of -$0.86 misses by $0.04.
Revenue of $4.21M (+29.1% Y/Y) misses by $0.23M.
Press Release
Posted by at No comments:

Analyst action, Nov. 6

Global Blood Therapeutics (NASDAQ:GBT) initiated with Hold rating and $50 (flat) price target at Canaccord Genuity.
Momenta Pharmaceuticals (NASDAQ:MNTA) initiated with Outperform rating and $32 (117% upside) price target at Wells Fargo.
Pacira BioSciences (NASDAQ:PCRX) initiated with Buy rating and $56 (33% upside) price target at BTIG Research.
Blueprint Medicines (NASDAQ:BPMC) upgraded to Strong Buy with a $112 (59% upside) at Raymond James. Shares up 4% premarket.
Inogen (NASDAQ:INGN) upgraded to Buy with a $90 (52% upside) price target at Needham. Shares up 15% premarket after Q3 beat.
Tenet Healthcare (NYSE:THC) upgraded to Outperform with a $36 (28% upside) price target at Credit Suisse.
Theravance Biopharma (NASDAQ:TBPH) upgraded to Neutral with an $18 (5% upside) price target at Baird.
Avanos Medical (NYSE:AVNS) downgraded to Market Perform with a $48 (30% upside) price target at Raymond James.
Fate Therapeutics (NASDAQ:FATE) downgraded to Market Perform with a $16 (2% upside) price target at Wells Fargo. Shares down 3% premarket.
Fluidigm (NASDAQ:FLDM) downgraded to Neutral with a $4 (22% downside risk) price target at Janney Montgomery Scott. Shares down 27% premarket after Q3 revenue miss.
Supernus Pharmaceuticals (NASDAQ:SUPN) downgraded to Hold with a $23 (21% downside risk) at Jefferies. Shares down 28% premarket after Q3 miss.
Posted by at No comments:

MannKind EPS beats by $0.02, misses on revenue

MannKind (NASDAQ:MNKD): Q3 GAAP EPS of -$0.05 beats by $0.02.
Revenue of $14.6M (+226.6% Y/Y) misses by $0.62M.
Press Release
Posted by at No comments:

Biogen expands biosimilar relationship with Bioepis

Biogen (NASDAQ:BIIB) intends to in-license two additional biosimilars, SB11 referencing Roche’s Lucentis and SB15 referencing Regeneron Pharmaceuticals’ Eylea, from Samsung Bioepis from major global markets, including the U.S., Canada, Europe, Japan and Australia.
It will also acquire exclusive commercialization rights to Bioepis’ anti-TNF portfolio, including Benepali (etanercept), Flixabi (infliximab) and Imraldi (adalimumab) in China and an option to expand its existing commercial agreement for the products into Europe.
Under the terms of the agreement, Biogen will pay Bioepis $100M upfront and up to $210M in milestones. Bioepis will be responsible for development and will supply Biogen at a pre-specified gross margin. Biogen will pay an additional $60M if it exercises its option in Europe.
The transaction should close this quarter.
Posted by at No comments:

ANI Pharmaceuticals EPS misses by $0.20, misses on revenue

ANI Pharmaceuticals (NASDAQ:ANIP): Q3 Non-GAAP EPS of $1.23 misses by $0.20; GAAP EPS of $0.32 misses by $0.32.
Revenue of $51.34M (+1.3% Y/Y) misses by $4.76M.
Shares +0.33% PM.
Press Release
Posted by at No comments:

Odonate Therapeutics EPS beats by $0.16

Odonate Therapeutics (NASDAQ:ODT): Q3 GAAP EPS of -$0.88 beats by $0.16.
Cash of $204.25M.
Press Release
Posted by at No comments:
Subscribe to: Comments (Atom)